Indications and uses
to temporarily relieve symptoms commonly associated with restless legs, such as: • twitching • jerking • burning • cramping • heaviness • pain
to temporarily relieve symptoms commonly associated with restless legs, such as: • twitching • jerking • burning • cramping • heaviness • pain
Dispense Restulex directly into mouth, or add recommended dosage into 8-12 oz of purified (non-chlorinated) water and drink. Safe for ages 2 and up. DOSAGE BY WEIGHT 30-50 lbs (13.6-22.6 kg) 1/2 mL twice per day 50+ lbs (22.6+ kg) 1 mL twice per day External Use: If needed, apply to affected areas 2-6 times daily until symptoms improve.
do not use if tamper seal is broken store in a cool, dry place product must not come in contact with metal do not store next to electrical devices or appliances
| Arsenicum album HPUS
Bufo rana HPUS Causticum HPUS Chamomilla HPUS Crotalus horridus HPUS Digitalis purpurea HPUS Lachesis mutus HPUS Lilium tigrinum HPUS Pulsatilla HPUS Rhus toxicodendron HPUS Sulphur HPUS Tarentula hispana HPUS Viscum album HPUS Zincum metallicum HPUS Each active ingredient contains equal volumes of 10X, 30X, and LM1 potencies. The letters “HPUS” indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States. Product indications are based on Homeopathic Materia Medica. |
|
Arsenicum album HPUS..............................Twitching
Bufo rana HPUS...........................................Numbness of limbs Causticum HPUS..........................................Pain Chamomilla HPUS.......................................Rheumatic pains Crotalus horridus HPUS..............................Cannot keep legs or feet still Digitalis purpurea HPUS..............................Rheumatic pains Lachesis mutus HPUS..................................Restlessness Lilium tigrinum HPUS..................................Burning of feet Pulsatilla HPUS............................................Jerking Rhus toxicodendron HPUS..........................Tingling in feet Sulphur HPUS..............................................Stiffness Tarentula hispana HPUS..............................Extraordinary movements Viscum album HPUS....................................Muscle tremors Zincum metallicum HPUS............................Trembling |
| to temporarily relieve symptoms commonly associated with restless legs, such as:
• twitching • jerking • burning • cramping • heaviness • pain |
Ask a doctor before use if
When using this product, use only as directed.
Stop use and ask a doctor if
symptoms persist or worsen.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of the reach of children.
Dispense Restulex directly into mouth, or add recommended dosage into 8-12 oz of purified (non-chlorinated) water and drink. Safe for ages 2 and up.
DOSAGE BY WEIGHT
30-50 lbs (13.6-22.6 kg) 1/2 mL twice per day
50+ lbs (22.6+ kg) 1 mL twice per day
External Use: If needed, apply to affected areas 2-6 times daily until symptoms improve.
| citric acid, potassium sorbate, purified ionized mineral water |
You can email us at
info@hellolife.net or call us toll-free at
1.800.875.0850 Monday through Friday 9am-5pm ET
Mftd for: HelloLife, LLC.
|
| NDC 49726-022-02
RESTULEX TM Restless Leg Symptom Relief To temporarily relieve symptoms commonly associated with restless legs, such as: • twitching • burning • heaviness • jerking • cramping • pain 2 fl oz (59 mL) Homeopathic (OTC) Medicine |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 63f39a63-5cd1-4016-bd86-2bbb0f6c3139 | Product name | 3 | 20240506 |
| e5a77e9c-c528-733a-173d-914a234c024b | Product name | 5 | 20240506 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49726-022-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-cc1c-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49726-022-02 | RestulexRestless Leg Symptom Relief | 59 mL in 1 BOTTLE, DROPPER | LIQUID | 59 | 11 | |
| 49726-022-02 | RestulexRestless Leg Symptom Relief | 1 in 1 CARTON | LIQUID | 1 | 11 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 49726-022 | RESTULEX RESTLESS LEG SYMPTOM RELIEF (ARSENICUM ALBUM, BUFO RANA, CAUSTICUM, CHAMOMILLA, CROTALUS HORRIDUS, DIGITALIS PURPUREA, LACHESIS MUTUS, LILIUM TIGRINUM, PULSATILLA, RHUS TOXICODENDRON, SULPHUR, TARENTULA HISPANA, VISCUM ALBUM, ZINCUM METALLICUM) LIQUID [HELLO LIFE, INC.] | 11 | Legacy NDC, 2 package rows | 20181227_10da19a2-8897-40ec-82ef-b8e925a5dd90.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 9 | |
| BUFO BUFO CUTANEOUS GLAND | ACTIVE INGREDIENT | Q59QU6N72Q | 9 | |
| CAUSTICUM | ACTIVE INGREDIENT | DD5FO1WKFU | 9 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE INGREDIENT | YHA2XLJ956 | 9 | |
| DIGITALIS | ACTIVE INGREDIENT | F1T8QT9U8B | 9 | |
| LACHESIS MUTA VENOM | ACTIVE INGREDIENT | VSW71SS07I | 9 | |
| LILIUM LANCIFOLIUM FLOWERING TOP | ACTIVE INGREDIENT | 6268MFA917 | 9 | |
| LYCOSA TARANTULA | ACTIVE INGREDIENT | 86M454L2TT | 9 | |
| MATRICARIA RECUTITA | ACTIVE INGREDIENT | G0R4UBI2ZZ | 9 | |
| PULSATILLA VULGARIS | ACTIVE INGREDIENT | I76KB35JEV | 9 | |
| SULFUR | ACTIVE INGREDIENT | 70FD1KFU70 | 9 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 9 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE INGREDIENT | BK9092J5MP | 9 | |
| ZINC | ACTIVE INGREDIENT | J41CSQ7QDS | 9 | |
| ARSENIC CATION (3+) | ACTIVE MOIETY | C96613F5AV | 9 | |
| BUFO BUFO CUTANEOUS GLAND | ACTIVE MOIETY | Q59QU6N72Q | 9 | |
| CAUSTICUM | ACTIVE MOIETY | DD5FO1WKFU | 9 | |
| CROTALUS HORRIDUS HORRIDUS VENOM | ACTIVE MOIETY | YHA2XLJ956 | 9 | |
| DIGITALIS | ACTIVE MOIETY | F1T8QT9U8B | 9 | |
| LACHESIS MUTA VENOM | ACTIVE MOIETY | VSW71SS07I | 9 | |
| LILIUM LANCIFOLIUM FLOWERING TOP | ACTIVE MOIETY | 6268MFA917 | 9 | |
| LYCOSA TARANTULA | ACTIVE MOIETY | 86M454L2TT | 9 | |
| MATRICARIA RECUTITA | ACTIVE MOIETY | G0R4UBI2ZZ | 9 | |
| PULSATILLA VULGARIS | ACTIVE MOIETY | I76KB35JEV | 9 | |
| SULFUR | ACTIVE MOIETY | 70FD1KFU70 | 9 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 9 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE MOIETY | BK9092J5MP | 9 | |
| ZINC | ACTIVE MOIETY | J41CSQ7QDS | 9 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 9 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 9 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 9 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49726-022 | 49726-022-02 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SUBCUTANEOUS | 28 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / INTRAVENOUS | 0.2 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / VAGINAL | 0.49 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAMUSCULAR | 28 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, FILM COATED / ORAL | 42 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING / ORAL | 83 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / ORAL | 446 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | AEROSOL, FOAM / TOPICAL | 8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRALESIONAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, CHEWABLE / ORAL | 7 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY, METERED / NASAL | 2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SPRAY, METERED / NASAL | 0.06 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DOUCHE / VAGINAL | 0.07 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CAPSULE / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / PERIDURAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION, EXTENDED RELEASE / ORAL | 140.8 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / AURICULAR (OTIC) | 0.04 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / IONTOPHORESIS | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / TOPICAL | 4 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAPLEURAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | POWDER, FOR SUSPENSION / ORAL | 19 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | OINTMENT / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SOFT TISSUE | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOAP / TOPICAL | 0.5 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRASYNOVIAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRATHECAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | EMULSION / OPHTHALMIC | 0.47 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / TOPICAL | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INHALANT / RESPIRATORY (INHALATION) | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7df183c1-5f52-1a16-e053-2991aa0a2223 | 10da19a2-8897-40ec-82ef-b8e925a5dd90 | 2018-12-26 | Warnings | 7df183c1-5f52-1a16-e053-2991aa0a2223 10da19a2-8897-40ec-82ef-b8e925a5dd90 |
Adverse event summaries are temporarily unavailable. Other product information remains available.